Abstract:Cabozantinib (CABOMETYX, Exelixis, Inc.) was recently approved by the US Food and Drug Administration (FDA) for the treatment of advanced renal cell carcinoma in patients who have received prior antiangiogenic therapy. The approval was based on a randomized study in which patients with advanced renal cell carcinoma, who had received a prior anti-angiogenic therapy, received either cabozantinib (60 mg orally once daily; N = 330) or everolimus (10 mg orally once daily; N = 328) [Approved drugs 2016]. There is increasing evidence that cabozantinib alone or in combination with other medications will be used to treat other cancers and has shown potency and efficacy in clinical preliminary trials. The more potential cabozantinib has, the greater our understanding of cabozantinib-associated cell biology and toxicology profiles should be. Cell biology and toxicology (CBT) profiles mainly include drug efficacy-driven or associated molecular interactions, mechanisms, or adverse effects on cells (Gu and Wang 2016). Cabozantinib as a small molecule receptor tyrosine kinase inhibitor, primarily targets ret protooncogene (RET)-encoded receptor tyrosine kinase (RTK), mesenchymal epithelial transition factor (MET), and the vascular endothelial cell growth factor receptor 2 (VEGFR2), of which VEGFR2 is more sensitive. Approximately 60 RTK proteins act as high-affinity cell surface receptors for many polypeptide growth factors, cytokines, hormones, and as key regulators of physiological and pathophysiological cellular processes, through the transmembrane and/or non-transmembrane domains (Kano et al. 2016; Li and Hristova 2010). One of the most important factors to influenceCBTprofiles of cabozantinib is the specificity and affinity of RTK binding types and efficacies in various conditions. In addition to bind RET, MET, and VEGFR2, cabozantinib can also inhibit KIT, VEGFR3, TRKB, VEGFR1, AXL, TIE2, and FLT3, in order of the efficacy according to IC50 values. RTK is also known as tyrosine receptor kinase or tyrosine kinase receptor depending on the permutation and has about 17 classes/families involved in major biological function and signaling through the cell membrane. Treatment with cabozantinib decreased tumor and endothelial cell proliferation and growth and increased apoptosis in a number of cancers though the inhibition of MET and VEGFR2 phosphorylation (Yakes et al. 2011). It is also reasonable to postulate the inhibitory effects of cabozantinib on tumor growth through targeting multi-RTKs, of which some may be unexpected. The binding specificity of cabozantinib as the critical part of biological function not only alters drug efficacy and efficiency but also drug side effects and toxicity, in tissues and systems or drug resistance to protein kinase inhibitors. The development of uncontrolled adverse effects and drug resistance of cabozantinib is a potential risk and challenge for clinicians to pay special attention to during application, due to the complex interplay of cabozantinib with multiRTKs, even though clinical trials have demonstrated Cell Biol Toxicol (2016) 32:259–261 DOI 10.1007/s10565-016-9349-6

Cabozantinib Reverses Multidrug Resistance of Human Hepatoma HepG2/adr Cells by Modulating the Function of P‐glycoprotein

Cabazitaxel, a Novel Chemotherapeutic Alternative for Drug-Resistant Hepatocellular Carcinoma.

Data from Cabozantinib Suppresses Tumor Growth and Metastasis in Hepatocellular Carcinoma by a Dual Blockade of VEGFR2 and MET

Cabozantinib-based combination therapy for the treatment of hepatocellular carcinoma

Cabozantinib inhibits the growth of lenvatinib-resistant hepatoma cells restoring FTCD expression

APG-1252 combined with Cabozantinib inhibits hepatocellular carcinoma by suppressing MEK/ERK and CREB/Bcl-xl pathways

APG-1252 combined with Cabozantinib inhibits hepatocellular carcinoma through MEK/ERK and CREB/Bcl-xl pathways

Cancer Therapy : Preclinical Cabozantinib Suppresses Tumor Growth and Metastasis in Hepatocellular Carcinoma by a Dual Blockade of VEGFR 2 and MET

Crizotinib (PF-02341066) reverses multidrug resistance in cancer cells by inhibiting the function of P-glycoprotein.

Bortezomib Overcomes Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Resistance in Hepatocellular Carcinoma Cells in Part Through the Inhibition of the Phosphatidylinositol 3-Kinase/akt Pathway

Rapamycin Enhances the Anti-Tumor Activity of Cabozantinib in Cmet Inhibitor-Resistant Hepatocellular Carcinoma

Mobocertinib antagonizes multidrug resistance in ABCB1- and ABCG2-overexpressing cancer cells: in vitro and in vivo studies

Immunogenic Cell Death and Immunomodulatory Effects of Cabozantinib

Tepotinib reverses ABCB1-mediated multidrug resistance in cancer cells.

Preventing NK cell activation in the damaged liver induced by cabozantinib/PD-1 blockade increases survival in hepatocellular carcinoma models

Cabozantinib prevents the progression of metabolic dysfunction-associated steatohepatitis by inhibiting the activation of hepatic stellate cell and macrophage and attenuating angiogenic activity

Data from Apatinib (YN968D1) Reverses Multidrug Resistance by Inhibiting the Efflux Function of Multiple ATP-Binding Cassette Transporters

Abstract 773: Crizotinib (PF-02341066) reverses multidrug resistance in cancer cells by inhibiting the function of P-glycoprotein

Chk1 Inhibitor Mk-8776 Restores The Sensitivity Of Chemotherapeutics In P-Glycoprotein Overexpressing Cancer Cells

CBT Profiles of Cabozantinib Approved for Advanced Renal Cell Carcinomas

Cabozantinib Carries the Risk of Drug-Drug Interactions Via Inhibition of UDPglucuronosyltransferase (UGT) 1A9